A Phase 1 Study of LY2787106 in Cancer and Anemia

A Phase 1 Safety Study of LY2787106 in Patients With Cancer and Anemia

This study will evaluate the safety LY2787106 in participants with cancer and anemia. It will also evaluate when LY2787106 can improve anemia. This study has two parts: Part A is a dose escalation evaluation. Part B is an evaluation of LY2787106 at a defined dose given with and without iron supplementation.

Study Overview

• Status: Completed
• Conditions: Anemia
• Intervention / Treatment: Drug: LY2787106; Dietary supplement: Iron Supplementation

• Study Type: Interventional
• Enrollment (Actual): 33
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • La Jolla, California, United States, 92093
      • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Santa Monica, California, United States, 90404
      • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  • Indiana
    • Indianapolis, Indiana, United States, 46202
      • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19106
      • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  • Texas
    • Dallas, Texas, United States, 75246
      • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Houston, Texas, United States, 77030
      • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • The Woodlands, Texas, United States, 77380
      • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
  • Washington
    • Seattle, Washington, United States, 98109
      • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    • Vancouver, Washington, United States, 98684
      • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Have histological or cytological evidence of non-myeloid cancer (solid tumors, lymphomas or multiple myeloma) that is metastatic and/or incurable
• Have been treated with at least one systemic (oral, intravenous, or subcutaneous) anti-cancer therapy or regimen
• Have a hemoglobin of less than or equal to 11 grams/deciliter (g/dL)
• Have a hepcidin level of greater than or equal to 5 nanograms/milliliter (ng/mL)
• Have given written informed consent prior to any study-specific procedures
• Have adequate hematologic, hepatic, and renal organ function
• Have an Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2
• Available for the duration of the study and willing to follow study procedures
• If male or female with reproductive potential: Must agree to use medically approved contraception during the trial and for 4 months following the last dose of study drug
• If female with child bearing potential: Have a negative serum pregnancy test
• Have an estimated life expectancy of greater than or equal to 12 weeks

Exclusion Criteria:

• Have received treatment in the previous 21 days with, or have not recovered fully from, a drug that has not received regulatory approval for any indication
• Have received erythropoiesis-stimulating agents in the previous 21 days or red blood cell transfusions in the previous 14 days, or in the investigator's opinion, likely to need red blood cell transfusion more frequently than every 21 days
• Have received parenteral iron supplementation within the prior 14 days
• Have a documented history of pure red cell aplasia, thalassemia major or sickle cell disease
• Have a history of cirrhosis or major organ transplantation
• QTc greater than 470 millisecond (msec)
• Have evidence of clinically significant hemolysis or bleeding
• Have a clinically significant systemic infection within 14 days of enrollment
• Have a suspected or confirmed history of hemochromatosis.
• Have other serious preexisting medical conditions (left to the discretion of the investigator)
• Have symptomatic central nervous system malignancy or metastasis (screening not required)
• Have acute or chronic leukemia
• Are a female who is pregnant or lactating
• Have a history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C (screening not required)
• Have received external beam radiotherapy to more than 25% of the bone marrow
• Have known clinically significant hypersensitivity to biologic agents
• Have received live vaccine(s) within 1 month of screening or with plans of doing that during the participation to the study
• Have a history of congestive heart failure with New York Heart Association (NYHA) Class greater than 2 (NYHA Class 1 and 2 are eligible), unstable angina or recent myocardial infarction (within 1 year prior to administration of study drug)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: LY2787106 Dose Escalation; Part A: Dose escalation starting at 0.3 milligram/kilogram (mg/kg), intravenously (IV), day one of up to three 21-day cycles.	Drug: LY2787106; Administered IV.
Experimental: 10 mg/kg LY2787106; Part B: 10 mg/kg of LY2787106, administered IV, on day one of up to eight 7-day cycles. Participants who do not experience a stopping rule and who are felt to be benefiting during the defined treatment period may receive additional doses at the discretion of the investigator.	Drug: LY2787106; Administered IV.
Experimental: 10 mg/kg LY2787106+Iron; Part B: 10 mg/kg of LY2787106, administered IV, on day one of up to eight 7-day cycles with daily oral iron supplementation. Participants who do not experience a stopping rule and who are felt to be benefiting during the defined treatment period may receive additional doses at the discretion of the investigator.	Drug: LY2787106; Administered IV.; Dietary supplement: Iron Supplementation; Administered orally.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Clinically Significant Events	Number of participants with one or more treatment emergent adverse event (TEAE) or any Serious AE (SAE). A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Event module.	Baseline to Study Completion (up to 5 Years)
Mean Change From Baseline in Hemoglobin With or Without Oral Iron Supplementation	This analysis assesses the mean change in Hemoglobin from baseline to the end of Cycle 4. The analysis was carried separately for Cohort B1 without supplemental iron and Cohort B2 with supplemental iron.	Baseline, Cycle 4 (7-day cycle)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetics (PK): Maximum Concentration (Cmax)	Cmax is the maximum serum concentration after a single IV dose of the study drug.	Days 1, 2, and 4 of Cycles 1 and 5, Day 1 of Cycles 2, 3, 4, 6, 7 and 8 (Part A 21-day cycles, Part B 7-day cycles) and 1, 3, and 9 weeks after the last infusion
PK: Area Under the Curve (AUC[0-∞])	AUC is the area under the concentration versus time curve from time zero to infinity.	Days 1, 2, and 4 of Cycles 1 and 5, Day 1 of Cycles 2, 3, 4, 6, 7 and 8 (Part A 21-day cycles, Part B 7-day cycles) and 1, 3, and 9 weeks after the last infusion
Recommended Dose for Future Studies: Maximum Tolerated Dose (MTD)	MTD is defined as being the highest tested dose below the level at which one-third or more of participants experience a Dose-limiting toxicity (DLT). DLT is defined as an adverse event occurring in any part of the study that is related to the study medication, occurs during Cycle 1 of Part A, and fulfills any one of the following criteria: Clinically significant Grade 2 toxicity, such as angina, arrhythmia, seizure, dyspnea, rash with significant blistering or desquamation, or other event deemed significant by either the investigator.; ≥Grade 3 anemia (excluding participants with baseline <9.0 g/dL) or hemoglobin (Hb) decrease >1.0 g/dL if baseline Hb <9.0 g/dL, confirmed by 2 independent measurements.; ≥ Grade 3 cytokine release syndrome/acute infusion reaction.; Other ≥ Grade 3 hematological or non-hematological toxicity.	Baseline to Cycle 1 of Part A
Change From Baseline in Serum Iron	Mean change in serum iron from baseline to the end of Cycle 4.	Baseline, Cycle 4 (7-day cycle)
Mean Change From Baseline in Reticulocyte Count	Mean change in reticulocyte count from baseline to the end of Cycle 4.	Baseline, Cycle 4 (7-day cycle)

Collaborators and Investigators

• Sponsor: Eli Lilly and Company

Publications and helpful links

General Publications

• Vadhan-Raj S, Abonour R, Goldman JW, Smith DA, Slapak CA, Ilaria RL Jr, Tiu RV, Wang X, Callies S, Cox J, Tuttle JL, Lau YK, Roeland EJ. A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol. 2017 Mar 21;10(1):73. doi: 10.1186/s13045-017-0427-x.

Study record dates

Study Major Dates

• Study Start: January 1, 2010
• Primary Completion (Actual): December 1, 2014
• Study Completion (Actual): December 1, 2014

Study Registration Dates

• First Submitted: January 28, 2011
• First Submitted That Met QC Criteria: April 22, 2011
• First Posted (Estimate): April 25, 2011

Study Record Updates

• Last Update Posted (Actual): October 3, 2018
• Last Update Submitted That Met QC Criteria: February 17, 2018
• Last Verified: February 1, 2018

More Information

Terms related to this study

• Keywords: Cancer Related Anemia
• Additional Relevant MeSH Terms: Hematologic Diseases; Anemia
• Other Study ID Numbers: 13131; I3S-MC-JABA (Other Identifier: Eli Lilly and Company)